You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 136 No. 12, December 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Genetics
 •Genetic Counseling/ Testing/ Therapy
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Tumor Necrosis Factor Receptor–Associated Periodic Syndrome

A Novel Syndrome With Cutaneous Manifestations

Jorge R. Toro, MD; Ivona Aksentijevich, MD; Keith Hull, MD; Jane Dean, MSN; Daniel L. Kastner, MD, PhD

Arch Dermatol. 2000;136:1487-1494.

Background  Tumor necrosis factor receptor–associated periodic syndrome (TRAPS) is an inflammatory disorder characterized by prolonged episodes of periodic fever and localized inflammation and dominantly inherited mutations in TNFRSF1A, the gene encoding the 55-kDa tumor necrosis factor receptor. To our knowledge, the cutaneous pathologic characteristics of TRAPS have not been described previously.

Objectives  To characterize the dermatologic manifestations of TRAPS by clinical, microscopic, and molecular methods, and to investigate its immunophenotype.

Design, Setting, and Patients  At the National Institutes of Health Clinical Center, Bethesda, Md, a tertiary care referral center, 25 patients with a clinical and molecular diagnosis of TRAPS were evaluated clinically and 10 biopsy specimens of lesional skin were examined by light microscopy and immunohistochemistry. Patients were screened for mutations in TNFRSF1A, the gene coding for the p55 tumor necrosis factor receptor.

Main Outcome Measures  Clinical, light microscopic, and immunohistochemical features.

Results  The skin eruption usually lasted 4 to 21 days (mean, 13 days). Of 25 patients, 21 (84%) presented with migratory erythematous macules and patches and 10 (40%) had edematous dermal plaques. Conjunctivitis, characterized by pain and redness and/or periorbital edema, was present in 11 patients (44%). Most patients had their first skin eruption during the first 2 years of life. All patients had fever associated with the skin eruption. Most patients had associated abdominal pain (22 [88%]) and myalgia (20 [80%]). Other symptoms included arthralgia (13 [52%]), pleuritic chest pain (10 [40%]), and headache (17 [68%]). Microscopic examination of 10 biopsy specimens of lesional skin showed a superficial and deep perivascular and interstitial infiltrate of lymphocytes and monocytes. None of the biopsy specimens showed multinucleated macrophages or granulomatous or leukocytoclastic vasculitis. The results of immunohistochemistry showed a perivascular infiltrate of CD3+, CD4+, CD8+, CD68+, CD79a-, and CD20- cells. All the mutations were missense mutations in exons 2 through 4 of TNFRSF1A, directly affecting the extracellular domain of the protein.

Conclusions  TRAPS is characterized by a spectrum of dermatologic findings, including migratory patches, edematous plaques, periorbital edema, and/or conjunctivitis. TRAPS is characterized by a perivascular dermal infiltrate of lymphocytes and monocytes.


From the National Cancer Institute (Dr Toro) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (Drs Aksentijevich, Hull, and Kastner and Ms Dean), National Institutes of Health, Bethesda, Md.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Autoinflammatory Diseases: Clinical and Genetic Advances
Farasat et al.
Arch Dermatol 2008;144:392-402.
ABSTRACT | FULL TEXT  

Periorbital and facial swelling due to dermatomyositis
Rafailidis et al.
CMAJ 2007;176:1580-1581.
FULL TEXT  

Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene
Ravet et al.
Ann Rheum Dis 2006;65:1158-1162.
ABSTRACT | FULL TEXT  

Small vessel vasculitis and relapsing panniculitis in tumour necrosis factor receptor associated periodic syndrome (TRAPS)
Lamprecht et al.
Ann Rheum Dis 2004;63:1518-1520.
ABSTRACT | FULL TEXT  

A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus
Ida et al.
Rheumatology (Oxford) 2004;43:1292-1299.
ABSTRACT | FULL TEXT  

Clinical and genetic aspects of the hereditary periodic fever syndromes
Grateau
Rheumatology (Oxford) 2004;43:410-415.
ABSTRACT | FULL TEXT  

Hereditary Periodic Fever
Drenth and van der Meer
NEJM 2001;345:1748-1757.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.